Clinical Trial

Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma

Name: Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma — clinical trial record (NCT07636252)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-06-04.

Trial Details

NCT Number	NCT07636252
Lead Sponsor	Sheba Medical Center
Conditions	Lung Adenocarcinoma, Malignant Pleural Effusions (Mpe)
Enrollment	400 participants
Start Date	2023-06-14
Primary Completion	2028-12-01 (estimated)
Study Completion	2030-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-23